This is a type of liver cancer that starts in the main cells of the liver. It's the most common type of primary liver cancer. It can range from a slow-growing tumor to a fast-growing one.
Every report comes from a Lived member, sent anonymously.
Have you tried Tecentriq (Atezolizumab) for Hepatocellular Carcinoma?
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, meaning cancer that starts in the liver's own main cells rather than spreading there from another organ. It is sometimes called hepatoma. Cancer that begins in the colon or breast and later appears in the liver is a different disease, treated according to where it started. HCC usually grows in a liver that has already been damaged for years, most often by scarring called cirrhosis. That background matters as much as the tumor itself: how well the rest of the liver still works shapes which treatments are possible and how a person feels day to day. Early HCC often causes no symptoms. When symptoms do appear, they can include pain or tenderness in the upper right belly, unexplained weight loss, swelling of the abdomen from fluid buildup, yellowing of the skin or eyes (jaundice), and easy bruising. Because these often come late, many cases are found through planned checkups in people known to be at risk.
Cirrhosis from any cause is the strongest risk factor, and more than 8 in 10 people with HCC have it. Among people with cirrhosis, roughly 2 in every 100 develop HCC each year. The common routes to cirrhosis include long-term hepatitis B or C infection, heavy alcohol use, and fatty liver disease linked to obesity and diabetes (now called metabolic dysfunction-associated steatotic liver disease, or MASLD, and formerly NAFLD). Rarer inherited conditions, such as hemochromatosis (iron overload), also raise risk. Two exceptions are worth knowing. Chronic hepatitis B can lead to HCC even without cirrhosis, sometimes at younger ages. Fatty liver disease can too: up to about 3 in 10 cases of fatty-liver-related HCC occur without cirrhosis. Alcohol and smoking add to risk on top of other liver disease. Much of this risk can be lowered. The hepatitis B vaccine prevents infection, and antiviral treatment for hepatitis B or C significantly lowers the chance of HCC, although people who already have cirrhosis remain at risk afterward. Having a risk factor does not mean someone will develop HCC.
For people at high risk, mainly those with cirrhosis or certain hepatitis B infections, liver specialists recommend checking for HCC about every 6 months with an ultrasound and a blood test for alpha-fetoprotein (AFP), a protein that some liver tumors release. The aim is to find tumors while they are small and still curable. AFP alone cannot confirm or rule out HCC, since many tumors do not raise it. When a spot is found, the next step is a CT or MRI scan done in several phases after a contrast injection. HCC has a distinctive pattern: it lights up as contrast first arrives and then fades faster than the surrounding liver. Unlike most cancers, HCC can often be diagnosed without a biopsy: in a person with cirrhosis or chronic hepatitis B, a spot of at least 1 cm with this typical pattern is enough. Radiologists grade spots on a scale (called LI-RADS) from clearly harmless to definitely HCC; uncertain spots are rechecked with repeat scans in a few months or sampled with a needle biopsy. People without cirrhosis or hepatitis B usually need a biopsy. Staging then looks at three things together: how much tumor there is and whether it has spread (a chest CT checks the lungs), how well the liver is working, and the person's general fitness. Most US centers use the Barcelona Clinic Liver Cancer (BCLC) system, which groups HCC from very early (stage 0, a single small tumor) through A (early, up to three small tumors), B (several tumors confined to the liver) and C (spread into blood vessels or beyond the liver) to D, where the liver itself is failing.
Treatment is planned around the tumor, the health of the rest of the liver and overall fitness, which is why decisions are best made by a team that includes liver specialists, surgeons, radiologists and oncologists. Being reviewed by such a team is linked to better care and survival. For early-stage HCC, the goal is cure. Surgery to remove part of the liver suits people with a single tumor and a liver that works well enough to recover; in well-chosen patients, more than 70% are alive five years later, though the cancer returns in about half or more. A liver transplant treats both the cancer and the damaged liver, so it suits people with early cancer whose liver is too scarred for surgery. Eligibility generally requires one tumor up to 5 cm or up to three tumors each no larger than 3 cm, and the wait for a donor organ is a real limitation. Ablation destroys a small tumor with heat (radiofrequency or microwave) through a needle and works best for tumors 3 cm or smaller. When there are several tumors still confined to the liver, treatments delivered through the liver's arteries are the usual approach. Chemoembolization (TACE) sends chemotherapy into the artery feeding the tumor and then blocks it; radioembolization uses tiny radioactive beads instead. These slow the cancer and lengthen life, and sometimes shrink it enough to make a transplant possible. Focused radiation is another option for some tumors. For advanced HCC, medicines given into a vein or by mouth aim to control the cancer and extend life, but usually do not cure it. Common first choices are immunotherapy combinations: atezolizumab (Tecentriq) with bevacizumab (Avastin), or durvalumab (Imfinzi) with tremelimumab (Imjudo). Immunotherapy helps the immune system attack the cancer and can occasionally cause inflammation in almost any organ. Bevacizumab blocks the blood supply tumors need and raises the risk of bleeding, so people starting it usually have an upper endoscopy first to look for and treat enlarged veins (varices) in the esophagus. Immunotherapy is generally avoided after a liver transplant because it can cause the body to reject the new liver. Daily pills such as lenvatinib (Lenvima) or sorafenib, targeted medicines that block signals tumors use to grow and build a blood supply, are alternatives when immunotherapy is unsuitable or stops working; common side effects include tiredness, diarrhea, sore skin on the hands and feet, and raised blood pressure. Most of the evidence for these medicines comes from people whose liver still worked fairly well. Palliative care, which focuses on comfort and quality of life, can be added at any stage. Treating the underlying liver disease, such as hepatitis B or C, and stopping alcohol remain part of care throughout.
The outlook depends heavily on how early HCC is found and on the health of the rest of the liver. Small tumors caught through regular checks can often be cured with surgery, transplant or ablation. Once the cancer has spread or the liver is failing, treatment shifts toward slowing it down and keeping a person well for as long as possible, and survival is measured in months to a few years rather than decades, though this varies widely. Even after successful treatment, the liver that produced one cancer can produce another. Follow-up scans of the abdomen and chest with AFP blood tests every 3 to 6 months are recommended for years after surgery. Many people move between treatments over time, for example ablation followed later by chemoembolization or medicines, as the cancer responds or returns. Daily life is often shaped by the underlying liver disease as well as the cancer: fatigue, appetite changes and fluid buildup can come from either. Treatment with medicines involves regular visits, blood tests and scans to check how the cancer is responding and to catch side effects early. For people with larger tumors or advanced disease, early conversations about goals and preferences (advance care planning) help keep treatment aligned with what matters to them.
If you have cirrhosis or chronic hepatitis B, ask your doctor whether you should have an ultrasound and AFP test every 6 months, and keep to that schedule even when you feel well. See a doctor about ongoing pain in the upper right belly, unexplained weight loss or a feeling of fullness, especially if you have known liver disease. If you already have HCC or cirrhosis, contact your care team promptly about new yellowing of the skin or eyes, a gradually swelling abdomen, or new or worsening symptoms during treatment, since side effects are easier to manage when caught early. Get emergency care right away for vomiting blood, black or bloody stools, new confusion or unusual drowsiness, or sudden severe belly pain or rapid swelling of the abdomen, which can signal internal bleeding or a sudden worsening of the liver.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hepatocellular Carcinoma is like, what's helped you, or ask the community a question.